In addition to the well-known estrogen receptor (ER) and the human epidermal growth factor receptor 2, the androgen receptor (AR) is also a potential drug target in breast cancer treatment. Whole body imaging can provide information across lesions within a patient. ER expression in tumor lesions can be visualized by 18 F-fluoroestradiol (FES) PET, and AR expression has been visualized in prostate cancer patients with 18 F-fluorodihydrotestosterone (FDHT) PET. Our aim was to assess the concordance between FDHT-and FES-PET and tumor AR-and ER-expression measured immunohistochemically in patients with metastatic breast cancer. Methods: Patients with ER-positive metastatic breast cancer were eligible for the study, irrespective of tumor AR-status. Concordance of FDHT and FES uptake on PET with immunohistochemical expression of AR and ER in biopsies of corresponding metastases was analyzed. Patients underwent FDHT-PET and FES-PET. A metastasis was biopsied within 8 weeks of the PET procedures. Tumor samples with >10% and >1% nuclear tumor cell staining were considered respectively AR-and ER-positive. Correlations between PET uptake and semi-quantitative immunohistochemical scoring (% positive cells x intensity) were calculated. The optimum threshold of SUV to discriminate positive and negative lesions for both AR and ER was determined by receiveroperating-characteristic (ROC) analysis. Results: In the 13 evaluable patients correlation between semi-quantitative AR-expression and FDHT uptake was R²: 0.47 (P = 0.01) and between semi-quantitative ER-expression and FES uptake was R²: 0.78 (P = 0.01). The optimal cutoff for AR-positive lesions was a SUVmax of 1.94 for FDHT-PET, yielding a sensitivity of 91% and a specificity of 100% and for FES-PET a SUV max of 1.54, resulted in a sensitivity and specificity of 100% for ER. Conclusion: FDHT and FES uptake correlate well with AR-and ER-expression levels in representative biopsies. These results show the potential use of whole-body imaging for receptor status assessment, particularly in view of biopsy-associated sampling errors and heterogeneous receptor expression in breast cancer metastases.
INTRODUCTION
The estrogen receptor (ER) is expressed in 75% of the breast carcinomas, which makes patients with such tumors eligible for ER-targeted therapy (1) . While the ER, human epidermal growth factor receptor 2 and progesterone receptor are routinely determined in breast cancer for prognosis and treatment decision-making, this is not the case for the androgen receptor (AR). Nevertheless, several studies have shown that the AR is also present in 70-80% of the breast carcinomas, which offers a potential new treatment strategy with AR affecting drugs (2) .
Patients with metastatic breast cancer received androgens in the first half of the 20 th century with response rates of 19-36% (3, 4) . However, side effects of androgens, including hirsutism and lowering of voice, combined with awareness of the conversion of androgens into estrogens resulted in the discontinuation of androgen therapy in breast cancer patients. With a number of emerging, less toxic AR-targeted therapies for patients with prostate cancer, and the development of resistance to current breast cancer treatment options, AR-targeted therapies in breast cancer have re-entered clinical trials.
A challenge in this era of rapidly emerging drug targets and treatment options is to administer the right drug to the right patient. It is well recognized that only those patients with ER-expressing tumors can benefit from endocrine therapies (1) . Since the ER is functionally and structurally highly comparable to the AR, response to AR-targeting drugs may also rely on AR-expression in the tumor.
Standard immunohistochemical staining of the primary tumor is inexpensive, easy to apply and well established in decision-making for adjuvant therapies. However, discordant ER-expression between the primary breast tumor and metastases has been observed in 18-40% of the patients (5) (6) (7) (8) . Molecular imaging offers the possibility to non-invasively determine the presence of relevant drug targets in all metastases within an individual patient. Tumor ERexpression can be visualized by 18 F-fluoroestradiol (FES) positron emission tomography (PET) in breast cancer patients (9) . AR-expression in prostate cancer patients has been evaluated using 18 F-fluorodihydrotestosterone (FDHT)-PET (10, 11) . If FDHT-PET is also able to determine the AR status in metastatic breast cancer patients, this technique has the potential to select patients eligible for AR-targeted therapies. The aim of the present study was to assess whether uptake on FES-and FDHT-PET correlates with levels of both ER-and AR-expression on a simultaneous biopsied metastasis.
MATERIALS AND METHODS Patients
Postmenopausal patients with metastatic breast cancer with previous ERpositive primary tumor were eligible if they had a metastasis outside the liver which was safe to biopsy. Patients were staged with full-body bone scintigraphy (bone scan) and a contrast-enhanced CT scan (chest/abdomen) within 6 weeks before the PET examinations. A tumor biopsy was performed within 8 weeks of the PET examinations. Exclusion criteria for the study were the use of ER ligands <6 weeks before entering the study, and a life expectancy of less than 3 months. Aromatase inhibitors and chemotherapy were allowed. All patients gave written informed consent prior to study participation, according to the Declaration of Helsinki and the protocol was approved by the local Ethical Committee (EudraCT Number: 2012-003981-42)
Study Design
We performed a prospective, two-center feasibility trial (NCT01988324). The primary endpoint was the concordance of FDHT and FES uptake with respectively AR-and ER-expression in a newly obtained biopsy of a metastasis measured by immunohistochemistry. Secondary endpoints were the optimum threshold to discriminate positive and negative lesions for both AR and ER on PET, inter-and intra-patient FDHT and FES heterogeneity, and the correlation between tracer uptake and serum hormone levels at the time of scanning. Venous blood was collected prior to FES tracer injection to evaluate serum estradiol (luminescence immune assay), luteinizing hormone, follicle stimulating hormone (both fluorescence immune assay) and sex hormonebinding globulin (chemiluminescence microparticle immune assay). These have been reported to affect tumor FES uptake in breast cancer studies (12) . Before FDHT injection, blood was collected for serum testosterone and dihydrotestosterone levels (both liquid chromatography-mass spectrometry assay).
Tumor histology
All patients underwent a biopsy of a metastasis, detectable by conventional imaging, within 8 weeks of the PET procedures. Biopsies were formalin fixed and paraffin embedded. Biopsies were centrally revised by a dedicated breast pathologist (BvdV). ER (CONFIRM anti-Estrogen Receptor (SP1) Rabbit Monoclonal Primary Antibody, Ventana, Illkirch, France) and AR (anti-Androgen Receptor (SP107) Rabbit Monoclonal Primary Antibody, Ventana, Illkirch, France) were stained with a Ventana Benchmark automated stainer (Ventana, Illkirch, France) at the Department of Pathology of the University Medical Center Groningen. Antibodies were prediluted by the supplier. ER was scored according to the American Society of Clinical Oncologypathologists guideline (13) and semi-quantitatively: the percentage of positive tumor nuclei was multiplied by the intensity of staining (0=negative; 1=weak, 2= moderate, and 3=strong). This led to a score of 0-300 (14) . As AR is not a routine staining in breast cancer, a threshold of >10% positive nuclear staining was used as a discriminator for AR positivity, based on current use in literature (2) .
Imaging CT scans were evaluated by a radiologist (AB). Bone scans were evaluated by two nuclear physicians (AG, OH). All tumor lesions visible on CT (> 1 cm) and bone scans were documented. Patients had a FDHT-PET and a FES-PET on separate days within 14 days. FES and FDHT were produced as described previously (15, 16) . Patients received approximately 200 MBq of FDHT and FES. Whole-body PET/CT was performed 60 minutes after tracer injection using a Siemens 64-slice mCT (PET/CT) (University Medical Center Groningen) or a Philips Gemini 64 TF PET/CT camera (VU university Medical Center) using the EANM Research Limited (EARL) approved protocols (17) . Low-dose CT (for attenuation and scatter correction) and PET imaging were performed within one procedure. All images were reconstructed according to the specifications of the EARL accreditation program (17) . Tumor FES uptake was quantified for all lesions seen on CT and bone scan, as well as for non-physiological uptake visible above background with a maximum standardized uptake value (SUV max ) >1.5 based on previous studies (18, 19) . All lesions detected on bone scan, CT and FES-PET were also quantified on the FDHT-PET scan. In line with previous studies, we used the SUV max to calculate tumor FDHT and FES uptake (18, 19) . We also measured the SUV mean using a 50% isocontour of the hottest pixel to assess the average SUV computed in the volume of interest. The SUV peak was used to calculate uptake in a 1 cm³ spherical volumes of interest surrounding the voxel with the highest activity). Background correction was applied using a volumes of interest at the unaffected contralateral site whenever available, or at the surrounding tissue of the same origin and deducted from the SUV of the tumor (i.e. lesion SUV max/mean/peak minus background SUV max/mean/peak , resulting in background corrected SUV max/mean/peak .
Statistical Analysis FDHT-PET/CT
and FES-PET/CT findings were compared with immunohistochemical findings for AR-and ER-expression, respectively. The optimum threshold of SUV to discriminate positive and negative lesions for both AR and ER was determined by receiver-operating-characteristic (ROC) analysis. Correlations between semi-quantitative receptor analysis and SUV were calculated using the Pearson correlation coefficient. A P-value of ≤ 0.05 was considered significant.
RESULTS

Patient Characteristics
Twenty-one patients were included between September 2014 and August 2015 ( Table 1 ) and 13 were evaluable for the primary study endpoint. Nonevaluable were five patients with a non-vital tumor biopsy (24%), and three patients (14%) with biopsied lesions not visible on conventional imaging or PET (n = 2 skin lesions, n = 1 intestinal lesion). All evaluable patients had an ER-positive and AR-positive primary breast cancer based on immunohistochemistry. Three patients (23%) showed conversion between the primary tumor and the metastasis of either ER (8%), AR (8%) or both (8%) measured with immunohistochemistry. Fig. 1 shows two representative examples of AR immunohistochemical staining results and corresponding FDHT-PET scans. Mean FDHT SUV max of the biopsies in AR-positive lesions was 3.1 (Standard deviation 0.90) versus a mean FDHT SUV max in AR-negative lesions of 1.9 (Standard deviation 0.01). Mean FES SUV max of the biopsied ER-positive lesions was 4.3 (standard deviation (SD) 2.4) versus a mean FES SUV max in biopsied ER-negative lesions of 1.1 (Standard deviation 0.4). The correlation between semi-quantitative ARexpression and FDHT uptake was R²: 0.47 (P = 0.01) and between semiquantitative ER-expression and FES uptake was R²: 0.78 (P = 0.01) ( Fig. 2) . Correction for background uptake did not improve the correlation between semi-quantitative AR-and ER-expression and FDHT and FES uptake, as background correction resulted in a correlation of R²: 0.39 and R²: 0.78, respectively. The correlations between immunohistochemistry and SUV peak, SUV mean and background corrected SUV peak and SUV mean did not differ from the correlations observed between immunohistochemistry and SUV max (Supplemental Table 1 ).
Concordance Between SUV and Immunohistochemistry of the Same Tumor Lesion
The optimal SUV max cutoff value for FDHT-PET was 1.9, leading to a sensitivity of 91% and a specificity of 100% (area under the curve 0.91, 95% CI 0.74-1.0). ROC analysis showed an optimal cutoff value for FES-PET to be SUV max 1.5, resulting in a sensitivity and specificity of 100%. Correction of tracer uptake for background or using SUV mean or SUV peak instead of SUV max did not improve the results (Supplemental Table 2 ).
Figure 1
Comparison of immunohistochemistry staining of the androgen receptor (AR) between an AR-negative (0% AR staining) lesion (A1) and an AR-positive (100% staining) lesion (B1). The bottom row shows horizontal FDHT-PET/ CT fusion images. Image A2 shows physiological uptake in the small intestines and kidneys and the arrow indicates the biopsied lesion (rib) with no visual enhanced uptake. Image B2 shows physiological uptake in the small intestines and high uptake throughout the pelvic bones. The arrow indicates the biopsied lesion in the iliac bone with visually enhanced uptake.
Heterogeneity in Uptake
Heterogeneity in lesion uptake was seen between patients and across lesions within individual patients for both FES and FDHT uptake. An example of a typical FDHT-and FES-PET is shown in Fig. 3 . With the cutoff at 1.9 for FDHT-PET, all patients had both FDHT-positive and FDHT-negative lesions. SUV max on FDHT for tumor lesions varied within patients (median 2.8, range 0.8-6.5) and between patients (median 2.7, range 1.7-3.7). Eleven out of 13 patients had visually both FES-positive and negative lesions. SUV max on FES-PET varied widely between lesions (median 3.2, range 0.6-12.2) and patients (median 2.4, range 1.3-6.0).
Figure 2
Correlation plot of semi-quantitative analysis of receptor status and the maximum standardized uptake value (SUV max ) as measured by PET scan for the androgen receptor (left) and estrogen receptor (right).
A total of 298 lesions were detected with either CT-scan (n = 95), bone scan (n = 126), or FES-PET (n = 239). The majority (81%) showed uptake above background on FES-PET. CT and/or bone scan identified 59 lesions that showed no FES uptake above background. FES-PET identified 48 lesions not visible on conventional imaging. In total 278 lesions could be used for FES-PET analysis. Due to high physiological background uptake near the lesion such as in liver and intestines, 20 lesions could not be reliably quantified. The majority of the lesions were in the bone (n = 219), 34 in lymph nodes and 25 were visceral lesions ( Fig. 4) . On FDHT-PET scans 196 lesions (66%) were visible above background of which 42 lesions could not be reliably quantified due to high physiologic background uptake near the lesion (e.g. the liver, blood vessels and intestines). 102 lesions were not visible above background, but were visible on either CT-scan, bone scan or FES-PET scan. In total 256 lesions were included for FDHT-PET analysis.
The majority of the lesions were bone lesions (n=222), 14 lesions were lymph nodes and the remaining 20 lesions were visceral lesions ( Fig. 5 ).
Uptake in healthy liver tissue was high on both FDHT-PET and FES-PET scans rendering analysis of liver metastases impossible. Mean liver uptake on FDHT was SUV mean was 4.4 (range 3.6 -5.8) versus mean liver uptake on FES SUV mean 12.8 (range 8. 2 -19.6) . Several lesions were non-quantfiable due to high blood pool accumulation on the FDHT-PET. The blood pool accumulation measured in the descending thoracic artery was higher on FDHT PET compared to FES PET: SUV mean 4.6 (range 3.8 -6.2) versus SUV mean of 1.3 (range 0.9 -2.1), respectively.
Correlation Between PET Uptake and Serum Hormone Levels and Sex Hormone-Binding Globulin
FDHT tumor uptake did not correlate with serum sex hormone-binding globulin, DHT or testosterone levels (Supplemental Table 3 -5) . Serum estradiol levels correlated positively with FES tumor uptake (R 2 = 0.52; P = 0.01). FES tumor uptake did not correlate with sex hormone-binding globulin, luteinizing hormone or follicle stimulating hormone serum levels. 
DISCUSSION
This is the first study in which the FDHT uptake is evaluated in breast cancer patents and in which FDHT tracer uptake was correlated with semiquantitative AR analysis in a biopsy of the corresponding metastasis. FDHT uptake shows a moderate correlation with AR-expression and FES uptake shows a strong correlation with ER-expression.
In this study we showed that FDHT can identify AR-positive metastases in breast cancer patients. FDHT PET may therefore be an interesting tool to select patients eligible for clinical trials with AR antagonists and to analyze the receptor occupancy of these drugs. AR-targeted therapy is not yet standard in breast cancer patients, but preliminary results of phase II trials are promising with stable disease in 35% of metastatic breast cancer patients (20, 21) . More clinical studies exploring the efficacy of AR-targeted therapy in AR-positive metastatic breast cancer are currently on-going (e.g. NCT00468715, NCT00755885). Even combined AR-and ER-targeted therapies are currently underway (NCT02910050, NCT02953860).
To date FDHT-PET has only been used in trials with metastatic prostate cancer patients. A comparison of 59 metastatic prostate cancer lesions visible on conventional imaging showed that 97% were also visible on the FDHT-PET (10) . Here conventional imaging also included FDG-PET. In our study we found that 66% of the lesions visible on conventional imaging were visible on FDHT-PET.
With serial FES-PET scans in patients treated with ER modulators such as fulvestrant, we were able to visualize residual ER availability during therapy, which was associated with early progression (22) . For other ER modulators such as GDC0810 and Z-endoxifen FES-PET provided information about ER occupancy and guided dose selection for phase II trials (23, 24) . FDHT uptake in tumor lesions of patients with prostate cancer diminished in three patients after treatment with high dose of testosterone. Treatment with the AR blocker enzalutamide also resulted in a reduced uptake on FDHT-PET in prostate cancer patients (10) . We are currently investigating the effect of the AR blocker bicalutamide on residual AR availability assessed by FDHT-PET in patients with metastatic breast cancer. Secondary endpoints are the relation between percentage decreased uptake on FDHT-PET and response to treatment measured by RECIST in case of measurable disease. (NCT02697032).
This study enforces the earlier observed correlation between FES uptake and ER-expression. Correlations between the FES-PET uptake parameters and immunohistochemistry on the metastatic biopsy using SUV max >1.5 showed a 100% sensitivity and specificity similar to previously published results (9, 18, 19) . The parameters SUV max , SUV mean and SUV peak , did not differ and correction for background did not influence the correlation. Therefore, for FES-PET analysis in the diagnostic setting, SUV max can be used and correction for background is not required. The correlation between uptake on FDHT-PET scan and immunohistochemical stainingwas lower compared to FES-PET and immunohistochemical staining. Kinetic properties and metabolism of FES and FDHT are similar (25, 26) . But FDHT has a lower relative binding affinity of 0.43 for AR compared to FES the binding affinity of 0.83 for ER (21) . Furthermore, SUV might not be the best quantification method for FDHT uptake. In a small study with 4 metastatic prostate cancer patients, SUV corrected for plasma FDHT concentration showed a better correlation (27).
We analyzed factors that potentially could influence tracer uptake such as circulating hormone levels. We found only estradiol levels to be correlated with higher uptake on FES-PET scans, which might be related to higher ERexpressions in tumor lesions in postmenopausal patients with higher residual estradiol levels. In fact, we found a correlation of R²: 0.42 (P = 0.02) between serum estradiol levels and ER-expression determined by immunohistochemical staining on a metastasis biopsy. There was no correlation between other serum hormone levels and FES or FDHT tumor uptake. These data indicate that physiological circulating hormone levels are too low to directly affect tracer uptake in the tumor. Tracer uptake can be influenced by volume, i.e. partial volume effect, where smaller tumor sizes results into underestimation of uptake (28). However, in our study there was no correlation found between the volumes of interest of the lesions and FES or FDHT uptake.
Due to the feasibility setting of this study only a limited number of patients were evaluable for primary endpoint. Therefore larger studies should confirm the optimal cutoff value for FDHT-PET. In our study five out of the 21 entered patients did not have vital tumor tissue in their metastatic biopsies. CT may have also shown bone lesions that were no longer active, as patients were heavily pre-treated. This might have resulted in an overestimation of FES and FDHT negative sites. Others have used FDG-PET to visualize hormone receptor-negative lesions. We refrained from doing so, as FDG-PET can also be negative in hormone receptor positive breast cancer lesions (29). PET imaging of hormone receptors also has some restrictions. Liver lesions are non-evaluable by FES-and FDHT-PET due to high uptake of both tracers in the liver. In addition, FDHT-PET has the disadvantage of high accumulation in the blood pool, rendering it difficult to analyze lesions in close proximity to large veins. This has also been described in a FDHT-PET study in prostate cancer patients (9) . If the FDHT-PET would be used as a diagnostic tool, this would be complementary to the current conventional imaging.
In our heavily pre-treated patient population hormone receptor conversion in the metastasis, when compared to the primary tumor, occurred in 23% of the patients. This is similar to previously reported conversion rates (7, 8) .
Heterogeneous uptake in tumor lesions on both FES-and FDHT-PET was seen in most patients, which suggests both receptor positive and negative lesions are present in one patient. Current guidelines advise to perform a biopsy when metastatic disease presents. This may not always be feasible. However when omitted changes in receptor status over time might lead to suboptimal therapy choices (30). FDHT and FES-PET have the potential to serve as a surrogate for metastasis biopsy, especially when lesions are difficult to access or sampling errors are prone to occur. 
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